Insider Selling: Twist Bioscience (NASDAQ:TWST) CEO Sells 2,265 Shares of Stock

Key Points

• Emily Leproust, CEO of Twist Bioscience, sold 2,265 shares at an average price of $25.76, totaling approximately $58,346, which represents a 0.36% decrease in her position.
• Twist Bioscience's stock is currently trading at $25.09, with a market cap of $1.51 billion and a fifty-two week low of $24.28.
• Twist Bioscience reported a quarterly earnings per share of (-$0.47), surpassing analyst expectations, and has received an average rating of "Moderate Buy" from research analysts.

Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) CEO Emily Leproust sold 2,265 shares of the company's stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $25.76, for a total transaction of $58,346.40. Following the completion of the sale, the chief executive officer owned 634,740 shares in the company, valued at approximately $16,350,902.40. This trade represents a 0.36% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Twist Bioscience Stock Down 0.0%

Shares of Twist Bioscience stock traded down $0.00 during trading on Wednesday, reaching $25.09. The company had a trading volume of 544,821 shares, compared to its average volume of 1,198,913. The company has a market cap of $1.51 billion, a price-to-earnings ratio of -17.37 and a beta of 2.31. The firm's fifty day moving average is $31.29 and its 200-day moving average is $34.55. The company has a debt-to-equity ratio of 0.03, a quick ratio of 3.60 and a current ratio of 3.90. Twist Bioscience Corporation has a fifty-two week low of $24.28 and a fifty-two week high of $55.33.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.07. The firm had revenue of $96.06 million for the quarter, compared to analyst estimates of $95.52 million. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the stock. Cowen reiterated a "buy" rating on shares of Twist Bioscience in a research note on Monday, August 4th. Evercore ISI set a $46.00 price objective on shares of Twist Bioscience in a research note on Monday, August 4th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Twist Bioscience currently has an average rating of "Moderate Buy" and an average price target of $49.40.

Institutional Investors Weigh In On Twist Bioscience

Several large investors have recently made changes to their positions in TWST. Versant Capital Management Inc boosted its holdings in shares of Twist Bioscience by 547.2% in the first quarter. Versant Capital Management Inc now owns 686 shares of the company's stock valued at $27,000 after acquiring an additional 580 shares in the last quarter. GAMMA Investing LLC boosted its holdings in shares of Twist Bioscience by 68.1% in the first quarter. GAMMA Investing LLC now owns 748 shares of the company's stock valued at $29,000 after acquiring an additional 303 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in shares of Twist Bioscience in the fourth quarter valued at approximately $58,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Twist Bioscience by 15.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company's stock valued at $85,000 after acquiring an additional 302 shares in the last quarter. Finally, Geneos Wealth Management Inc. bought a new position in shares of Twist Bioscience in the second quarter valued at approximately $97,000.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.